Variation of choroidal Thickness 15 days after the first ranibizumab intravitreal injection in naive patients WIth Neovascular age-related macular degeneration: pilot Study. –

Trial Profile

Variation of choroidal Thickness 15 days after the first ranibizumab intravitreal injection in naive patients WIth Neovascular age-related macular degeneration: pilot Study. –

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 May 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 May 2016 Status changed from recruiting to completed, as per results published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
    • 17 May 2016 Primary endpoint has not been met. (Variation of choroidal thickness from baseline visit (first ranibizumab injection) to day 15.), as per results published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
    • 17 May 2016 Results published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top